Abstract:Background: Epilepsy is a serious neurological disorder that affects millions of people each year, often leading to cognitive issues and reduced quality of life. Medication is the main treatment, but many patients experience negative side effects. Male Sprague-Dawley (SD) rats were chosen as experimental animals for this experiment due to their physiological and genetic similarities to humans, cost-effectiveness, and ease of handling in a laboratory setting. Aims: The objective of this study was to assess the neuroprotective properties of baicalin (BA) in relation to its impact on anxiety and depressive-like behaviors in the epilepsy model. Methods: Thirty male Sprague-Dawley (SD) rats were selected for this experiment. Pentylenetetrazol (PTZ) kindling (40 mg/kg; i.p.) was utilized to establish an epilepsy model. The effect of BA (50 mg/kg; gavage) on seizure severity (assessed using the Racine scale), anxiety, and depressive- like behaviors (evaluated through open field experiments and forced swimming tests) was examined. Histological examinations, including hematoxylin and eosin (HE) staining and Nissl staining, were conducted to assess neuronal damage. Furthermore, the neuroprotective properties of BA were examined through the analysis of Doublecortin (DCX), MKI67 (KI67), and Brain-Derived Neurotrophic Factor (BDNF) levels in the hippocampus of rats. The inhibitory impact of BA on neuroinflammation was assessed via dual labeling for NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and the microglial marker ionized calcium- binding adapter molecule 1 (Iba-1). The influence of BA on the expression of P2X7 receptor (P2X7R), NLRP3, and Interleukin-1β (IL-1β) was also assessed by reverse transcription quantitative PCR (RT-qPCR) in the brain. Finally, we employed a molecular docking model to assess the extent of receptor-ligand binding. Results: Epilepsy models exhibited significant anxiety and depressive-like behaviors, and BA significantly reduced the severity of seizures in these rats while also alleviating their anxiety and depressive-like behaviors. Moreover, neuronal loss and damage were observed in the hippocampus of epileptic rats, but BA was able to effectively counteract this issue by enhancing BDNF expression and promoting neurogenesis within the hippocampus, especially in the DG region. The co-localization of Iba-1 with NLRP3 indicated the activation of NLRP3 inflammasome in microglia. Subsequent RT-PCR revealed that BA may alleviate anxiety and depressive-like behaviors in epileptic rats by activating the P2RX7/NLRP3/ IL-1β signaling pathway. The final molecular docking results indicated that BA had a good binding affinity with proteins, such as P2RX7, NLRP3, and IL-1β. Conclusion: This study confirmed the effectiveness of BA in improving anxiety and depressivelike behaviors associated with epilepsy. Moreover, it provides theoretical support for the neuroprotective role demonstrated by BA.

The P2X7 receptor in activated microglia promotes depression- and anxiety-like behaviors in lithium -pilocarpine induced epileptic rats

N-methyl-d-aspartate Receptor NR2B Subunit Involved in Depression-Like Behaviours in Lithium Chloride-Pilocarpine Chronic Rat Epilepsy Model

Transient Receptor Potential Melastatin 2 Contributes to Neuroinflammation and Negatively Regulates Cognitive Outcomes in a Pilocarpine-Induced Mouse Model of Epilepsy.

Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence

P2X7 Receptor Inhibition Prevents Atrial Fibrillation in Rodent Models of Depression.

The Anti-Depression Effect of Xylaria Nigripes in Patients with Epilepsy: A Multicenter Randomized Double-Blind Study.

Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats

A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model

A Sub-Threshold Dose of Pilocarpine Increases Glutamine Synthetase in Reactive Astrocytes and Enhances the Progression of Amygdaloid-Kindling Epilepsy in Rats

Anti-inflammatory Treatment with a Soluble Epoxide Hydrolase Inhibitor Attenuates Seizures and Epilepsy-Associated Depression in the LiCl-pilocarpine Post-Status Epilepticus Rat Model.

Gentiopicroside Attenuates Lithium/Pilocarpine-Induced Epilepsy Seizures by Down-Regulating NR2B/CaMKII/CREB and TLR4/NF-κB Signaling Pathways in the Hippocampus of Mice

Cannabinoid Receptor 2 Agonist AM1241 Alleviates Epileptic Seizures and Epilepsy-Associated Depression Via Inhibiting Neuroinflammation in a Pilocarpine-Induced Chronic Epilepsy Mouse Model

Microglia as a Game Changer in Epilepsy Comorbid Depression

Inhibition of P2X7 Receptor Ameliorates Nuclear Factor-Kappa B Mediated Neuroinflammation Induced by Status Epilepticus in Rat Hippocampus

Angiotensin II and Its Receptor in Activated Microglia Enhanced Neuronal Loss and Cognitive Impairment Following Pilocarpine-Induced Status Epilepticus

Antagonist Targeting microRNA-155 Protects against Lithium-Pilocarpine-Induced Status Epilepticus in C57BL/6 Mice by Activating Brain-Derived Neurotrophic Factor.

P2X7 receptor-mediated depression-like reactions arising in the mouse medial prefrontal cortex

Serotonin 1A Receptor Inhibits the Status Epilepticus Induced by Lithium-Pilocarpine in Rats

microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus

Demyelination contributes to depression comorbidity in a rat model of chronic epilepsy via dysregulation of Olig2/LINGO-1 and disturbance of calcium homeostasis.

[Saikosaponin a alleviates pentylenetetrazol-induced acute epileptic seizures in mouse models of depression by suppressing microglia activation-mediated inflammation]